HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Hardy, T. Articles by Boulton, A. J.M. Search for Related Content PubMed PubMed Citation Articles by Hardy, T. Articles by Boulton, A. J.M. Social Bookmarking                What's this?

Does Treatment With Duloxetine for Neuropathic Pain Impact Glycemic Control?

¹ Eli Lilly, Indianapolis, Indiana
² Department of Internal Medicine, Southwestern Medical Center, University of Texas, Dallas, Texas
³ Division of Endocrinology, Metabolism, and Diabetes, University of Miami School of Medicine, Miami, Florida
⁴ University Department of Medicine, Manchester Royal Infirmary, Manchester, U.K.

Address correspondence and reprint requests to Thomas Hardy, MD, PhD, Eli Lilly, Lilly Corporate Center DC 2138, Indianapolis, IN 46285. E-mail: hardyta{at}lilly.com

OBJECTIVE—We examined changes in metabolic parameters in clinical trials of duloxetine for diabetic peripheral neuropathic pain (DPNP).

RESEARCH DESIGN AND METHODS—Data were pooled from three similarly designed clinical trials. Adults with diabetes and DPNP (n = 1,024) were randomized to 60 mg duloxetine q.d., 60 mg b.i.d., or placebo for 12 weeks. Subjects (n = 867) were re-randomized to 60 mg duloxetine b.i.d. or routine care for an additional 52 weeks. Mean changes in plasma glucose, lipids, and weight were evaluated. Regression and subgroup analyses were used to identify relationships between metabolic measures and demographic, clinical, and electrophysiological parameters.

RESULTS—Duloxetine treatment resulted in modest increases in fasting plasma glucose in short- and long-term studies (0.50 and 0.67 mmol/l, respectively). A1C did not increase in placebo-controlled studies; however, a greater increase was seen relative to routine care in long-term studies (0.52 vs. 0.19%). Short-term duloxetine treatment resulted in mean weight loss (–1.03 kg; P < 0.001 vs. placebo), whereas slight, nonsignificant weight gain was seen in both duloxetine and routine care groups with longer treatment. Between-group differences were seen for some lipid parameters, but these changes were generally small. Metabolic changes did not appear to impact improvement in pain severity seen with duloxetine, and nerve conduction was also not significantly impacted by treatment.

CONCLUSIONS—Duloxetine treatment was associated with modest changes in glycemia in patients with DPNP. Other metabolic changes were limited and of uncertain significance. These changes did not impact the significant improvement in pain observed with duloxetine treatment.

Abbreviations: BPI, brief pain inventory • DPN, diabetic peripheral neuropathy • DPNP, DPN pain • FPG, fasting plasma glucose • TCA, tricyclic antidepressant

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?